Spyre Therapeutics, Inc. (SYRE)
| Market Cap | 7.26B +687.1% |
| Revenue (ttm) | n/a |
| Net Income | -148.70M |
| EPS | -2.17 |
| Shares Out | 86.84M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,148,881 |
| Open | 81.57 |
| Previous Close | 80.79 |
| Day's Range | 80.79 - 84.69 |
| 52-Week Range | 13.93 - 84.69 |
| Beta | 3.06 |
| Analysts | Strong Buy |
| Price Target | 98.53 (+17.89%) |
| Earnings Date | Aug 4, 2026 |
About SYRE
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the α4β7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn’s disease); and SPY002 and SPY072 – anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also develo... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for SYRE stock is "Strong Buy." The 12-month stock price target is $98.53, which is an increase of 17.89% from the latest price.
News
Spyre Therapeutics price target raised to $112 from $98 at BTIG
BTIG raised the firm’s price target on Spyre Therapeutics (SYRE) to $112 from $98 and keeps a Buy rating on the shares. SPY002 SKYLINE Part A monotherapy data support an…
Spyre says bowel disease drug cuts inflammation in mid-stage trial
Spyre Therapeutics said on Monday its experimental bowel disease drug met the main goal of significantly reducing disease severity in a mid-stage trial.
Spyre Therapeutics announces SKYLINE trial achieves primary endpoint
Spyre Therapeutics (SYRE) announced 12-week induction data from Part A of the Phase 2 SKYLINE trial of SPY002, an anti-TL1A being investigated for the treatment of moderately-to-severely active ulcera...
Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
SPY002 met its primary endpoint with a statistically significant reduction of 10.7 points (p
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sect...
Spyre Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The company is advancing a pipeline of long-acting, co-formulatable antibodies for autoimmune diseases, with multiple phase II readouts expected in the next year and combination therapy data in 2027. Strategic focus includes both IBD and rheumatic diseases, leveraging unique technology to optimize efficacy and safety. Commercial launches are targeted for early next decade.
Spyre Therapeutics Announces Grants of Inducement Awards
WALTHAM, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation the...
Spyre Therapeutics price target raised to $115 from $102 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Spyre Therapeutics (SYRE) to $115 from $102 and keeps a Buy rating on the shares. Competitor Abivax (ABVX) traded down 30% since…
Spyre Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
The team is advancing a portfolio of optimized antibodies for autoimmune diseases, focusing on both monotherapies and combinations to improve efficacy and convenience. Multiple phase II readouts are expected this year, with pivotal data to inform phase III strategies and commercial prioritization.
Spyre Therapeutics completes enrollment in SKYWAY basket trial of SPY072
Spyre Therapeutics (SYRE) announced the completion of enrollment for all sub-studies in the SKYWAY basket trial of SPY072 in rheumatic diseases.
Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA
Enrollment for psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) sub-studies of the SKYWAY basket trial are complete
Spyre Therapeutics Slides: Corporate presentation
Spyre Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
Spyre Therapeutics management to meet with BTIG
Biotechnology Analyst Harrison, along with a leading inflammatory bowel disease Key Opinion Leader and CEO Turtle, hold a dinner meeting in New York on June 2 at 6 pm hosted…
Spyre Therapeutics Transcript: AGM 2026
The meeting was held virtually, with a quorum confirmed and all proposals—including director elections, executive compensation, auditor ratification, and an amended stock plan—approved by preliminary vote. Final results will be filed with the SEC.
Spyre Therapeutics to Participate in Upcoming June Investor Conferences
WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine...
Spyre Therapeutics price target raised to $102 from $86 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Spyre Therapeutics (SYRE) to $102 from $86 and keeps a Buy rating on the shares.
Spyre Therapeutics price target raised to $97 from $64 at Citi
Citi analyst Samantha Semenkow raised the firm’s price target on Spyre Therapeutics (SYRE) to $97 from $64 and keeps a Buy rating on the shares.
Spyre Therapeutics price target raised to $107 from $92 at Stifel
Stifel analyst Alex Thompson raised the firm’s price target on Spyre Therapeutics (SYRE) to $107 from $92 and keeps a Buy rating on the shares.
Spyre Therapeutics reports Q1 EPS (74c), consensus (65c)
“With our first Phase 2 readout of the year supporting a potential best-in-class profile for SPY001 in IBD, we have begun to deliver on the promise of what we believe…
Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Announced positive topline induction data from Part A of the Phase 2 SKYLINE trial of SPY001, demonstrating best-in-class efficacy potential and a safety profile consistent with the α4β7 class Announ...
Spyre Therapeutics Quarterly report: Q1 2026
Spyre Therapeutics has published its Q1 2026 quarterly earnings report on May 5, 2026.
Spyre Therapeutics Earnings release: Q1 2026
Spyre Therapeutics released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Spyre Therapeutics price target raised to $95 from $64 at JonesResearch
JonesResearch raised the firm’s price target on Spyre Therapeutics (SYRE) to $95 from $64 and keeps a Buy rating on the shares after the company reported the SPY001 monotherapy topline…
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million
WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and anti...
Spyre Therapeutics 6.5M share Secondary priced at $62.00
The deal size was increased to $403M in common stock from $300M in common stock. Jefferies, Goldman Sachs, Evercore ISI and Guggenheim acted as joint book running managers for the…